XYLEM
27.8.2024 22:30:30 CEST | Business Wire | Press release
Christopher Whitfield and Wenqi (Jonathan) Zhao from the United Kingdom receive the prestigious Stockholm Junior Water Prize 2024 for their work on PFAS pollution in the Thames Basin. HRH Crown Princess Victoria of Sweden presented the winners with their award during a ceremony at World Water Week in Stockholm.
Per- and polyfluoroalkyl substances (PFAS) pollution is a growing concern worldwide. Focusing on the Thames Basin in the United Kingdom, where there are with no equitable solutions to the problem, Whitfield and Zhao developed a geospatial neural network, predicting PFAS values to within 10 percent of experimentally validated values.
For this, they were announced the winners of the Stockholm Junior Water Prize, an international competition where students between the ages of 15 and 20 present solutions to major water challenges.
Speaking on winning the prize, Zhao said, “We are very proud to have won this prize. It has been an amazing stay here in Sweden with so many new friends”.
The Jury noted that Whitfield and Zhao “find a way to take data and turn it into actionable knowledge. [They have] identified PFAS hotspots using machine learning, field tested their results, developed a cost-effective filtration system, and reached out to local governments and environmental organizations to raise awareness.”
The winners were presented with their prize during an award ceremony at World Water Week by HRH Crown Princess Victoria of Sweden, the Prize’s Official Patron.
The Diploma of Excellence was awarded to Shanni Valeria Mora Fajardo and Rosa Mendoza Sosa from Mexico for their work on how to reuse inked water with homemade filtration to produce veggie gardens.
The People’s Choice Award went to Manoel José Nunes Neto from Brazil, completing the line-up of winners.
The Stockholm Junior Water Prize has been organized every year since 1997. It is hosted by the Stockholm Water Foundation, with Xylem as Founding Partner.
“Innovation is paving the way to a more water-secure world, and the next generation are accelerating progress. The Stockholm Junior Water Prize competitors are an inspiring example of the ingenuity and passion young innovators bring to the table. On behalf of Xylem, I’d like to congratulate all those who took part in this year’s competition,” said Austin Alexander, Vice President of Sustainability and Social Impact at Xylem.
Read more about the winning projects:
- Stockholm Junior Water Prize: United Kingdom
- Diploma of Excellence: Mexico
- People’s Choice Award: Brazil
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240827691002/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
SINOVAC Receives Nasdaq Notification Regarding Late Filing of 2025 Annual Report29.5.2026 22:01:00 CEST | Press release
Sinovac Biotech Ltd. (Nasdaq: SVA) (“SINOVAC” or the “Company”), a leading provider of biopharmaceutical products in China, today announced that it received a notification letter dated May 20, 2026 (the “Notification Letter”), from Nasdaq Listing Qualifications (“Nasdaq”) stating that as of May 8, 2026, the Company had regained compliance with the periodic filing and interim financial requirements in Nasdaq Listing Rules 5250(c)(1) (the “Periodic Filing Rule”) and 5250(c)(2), as required by the Panel’s decision dated January 21, 2026. As previously disclosed on January 22, 2026, under the Panel’s decision, SINOVAC was required to, on or before May 11, 2026, demonstrate compliance with such Nasdaq Listing Rules by completing filings of its annual report for the year ended December 31, 2024, on Form 20-F and an interim balance sheet and income statement as of the end of its second quarter of 2025 on Form 6-K. The Company timely completed such filings as required by the Panel’s decision.
From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 15:00:00 CEST | Press release
Newest expansion of the NetBrain platform delivers Agent Skills, AI Path Doctor, MCP Server, and expanded cross-domain integrations, extending the agentic capabilities already running in production at hundreds of enterprises. NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under
Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 14:00:00 CEST | Press release
News summary: Non-practicing entity litigation continues to create costly, time-consuming pressure across the technology industry Adtran has reached a full settlement following counterclaims, with payment made to Adtran and all claims dismissed with prejudice Outcome reflects Adtran’s commitment to defend its innovations, customers and business against meritless patent assertions Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consi
Meiji Seika Pharma Invests in GHIC’s Global Health Security Fund29.5.2026 13:00:00 CEST | Press release
Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, Japan; President and Representative Director: Toshiaki Nagasato) today announced that it has committed to invest in the Global Health Security Fund (GHSF), which is sponsored by Global Health Investment Corporation (GHIC), a New York-based nonprofit organization. Through this investment, Meiji Seika Pharma will support the acceleration of innovations addressing critical global health challenges, including pandemic preparedness and antimicrobial resistance (AMR). GHIC is a mission‑driven nonprofit organization that deploys private investment strategies to generate both global health impact and financial returns. GHIC recently closed its second fund in GHSF. With more than a decade of experience investing in the field of infectious disease, GHIC has contributed to addressing major global health challenges. Its portfolio companies have successfully commercialized more than a dozen products, collectively reaching over 600 million people wo
IFF Enters Into Agreement to Sell Its Food Ingredients Business to CVC29.5.2026 12:50:00 CEST | Press release
Transaction advances portfolio transformation, sharpens focus on higher-growth, higher-margin businesses, strengthens balance sheet, and enhances value creation for shareholders IFF (NYSE: IFF), a global leader in flavors, fragrances, food ingredients, and health and biosciences, today announced that it has entered into an agreement to sell its Food Ingredients business to funds advised by CVC Capital Partners, a leading global private markets manager, in a transaction that values the business at approximately $4.3 billion, representing an enterprise value-to-EBITDA multiple of approximately 10x. As part of the transaction, IFF has chosen to retain an approximately 10% minority equity interest in the business, or approximately $200 million, permitting continued collaboration and cooperation between IFF and Food Ingredients and allowing IFF and its shareholders to participate in future value creation under its new ownership. The transaction marks a significant step in IFF’s portfolio tr
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom